A Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Achillion Pharmaceuticals
- 15 May 2017 Status changed from recruiting to completed.
- 14 Jun 2016 Status changed from planning to not yet recruiting.
- 14 Jun 2016 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12616000568415p).